SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00283387

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria

The aim of this study is to assess the efficacy and safety of betaine in reducing urine oxalate excretion of Type 1 Primary Hyperoxaluria (PHI) patients. Hypothesis: Betaine will effectively reduce urine oxalate excretion in Primary Hyperoxaluria Type I patients.

NCT00283387 Hyperoxaluria
MeSH: Hyperoxaluria, Primary

2 Interventions

Name: Betaine

Description: Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.

Type: Drug

Betaine Placebo

Name: Placebo

Description: Subjects received oral lactose placebo, in two doses daily, for 2 months.

Type: Drug

Betaine Placebo


Primary Outcomes

Description: The patients were randomly assigned oral betaine or placebo for 2 months, followed by a 2 month washout. Each patient then received the alternate study medication for 2 months. Urinary Oxalate Excretion was measured by oxalate oxidase. Two 24 hour urine collections were obtained at baseline, and during the eighth week of each study period.

Measure: Urinary Oxalate Excretion

Time: baseline, 2 months, 6 months

Purpose: Treatment

Allocation: Randomized

Crossover Assignment


There is one SNP

SNPs


1 G170R

Exclusion Criteria: 1. Patients who are fully VB6 responsive (i.e., G170R homozygotes). --- G170R ---

Hyperoxaluria Hyperoxaluria, Primary Our prior genotyping results have shown an association between the G170R allele and the clinical response to VB6. --- G170R ---

Since VB6 is a safe and completely effective treatment for patients homozygous for G170R, we will not study betaine in this group. --- G170R ---

Instead, 20 participants older than 6 years of age who are G170R compound heterozygous, non-G170R missense or truncating sequence change homozygous or heterozygous, will be selected for enrollment. --- G170R ---

Instead, 20 participants older than 6 years of age who are G170R compound heterozygous, non-G170R missense or truncating sequence change homozygous or heterozygous, will be selected for enrollment. --- G170R --- --- G170R ---

Participants in whom VB6 provides a partial reduction in urine oxalate excretion (compound heterozygotes for the G170R mutation) will be maintained on a stable dose of VB6 (8 mg/kg/d) for two months before and throughout betaine treatment. --- G170R ---



HPO Nodes